BBA
URGN icon

Baker Bros. Advisors’s UroGen Pharma URGN Stock Holding History

Baker Bros. Advisors’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-672,912
Closed -$12M – 119
2020
Q1 		$12M Sell
672,912
-158,576
-19% -$4.28M 0.07% 47
2019
Q4 		$27.7M Buy
831,488
+83,737
+11% +$2.29M 0.15% 43
2019
Q3 		$17.8M Buy
+747,751
New +$24.4M 0.12% 41

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HCM
Horton Capital Management Philadelphia, Pennsylvania $44.9M AUM 24.87% 1-Year Est. Return

Baker Bros. Advisors's URGN Position: Q2 2020 in Review

Baker Bros. Advisors sold out of UroGen Pharma (URGN) in Q2 2020, closing a stake of 672,912 shares — an estimated $12M sold.

Baker Bros. Advisors first reported a position in URGN in Q3 2019 and held it in 3 quarters. The position peaked at $27.7M in Q4 2019. 84 funds tracked by Wall St. Rank hold URGN as of Q2 2020.

  • Baker Bros. Advisors reported no remaining UroGen Pharma position as of Q2 2020 after selling out during the quarter.
  • Baker Bros. Advisors sold 672,912 UroGen Pharma shares in Q2 2020, an estimated $12M.
  • Baker Bros. Advisors first reported a position in UroGen Pharma in Q3 2019 and held it in 3 quarters.
  • Baker Bros. Advisors's UroGen Pharma position peaked at $27.7M in Q4 2019.
  • 84 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2020.

Based on Baker Bros. Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.